Albuminuria in non-primary renal disease: Risk marker rather than risk factor

Nephrology Dialysis Transplantation

Volumn 25, Issue 3, 2010, Pages 656-658

  De Jong, Paul E ^a   Gansevoort, Ron T ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Albuminuria; Chronic kidney disease; Diabetes; Microalbuminuria

Indexed keywords

ALBUMINURIA; DIABETES MELLITUS; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; KIDNEY DISEASE; MICROALBUMINURIA; NOTE; PRIORITY JOURNAL; RISK FACTOR;

ALBUMINURIA; BIOLOGICAL MARKERS; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; KIDNEY DISEASES; RISK FACTORS;

EID: 77649217358     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp691     Document Type: Note

References (14)

1. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1986; 310: 356-360
2. Parving HH, Oxenbøll B, Svendsen PA, et al. Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion. Acta Endocrinol (Copenh) 1982; 100: 550-555
3. Parving HH, Lehnert H, Bröchner-Mortensen J. The effect of irbesar-tan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878 (Pubitemid 34940826)
4. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951
5. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GI-SEN) Group. Randomised placebo-controlled trial of effect of rami-pril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863
6. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angioten-sin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139: 244-252
7. De Jong PE, Navis GJ, de Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet 1999; 354: 352-353[com-mentary]
8. Asselbergs FW, Diercks GFH, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbu-minuria. Circulation 2004; 110: 2809-2816
9. Lorenzo V, Saracho R, Zamora J, et al. Similar renal decline in diabetic and non-diabetic patients with comparable levels of albuminuria. Nephrol Dial Transplant 2009
10. Gansevoort RT, van der Heij B, Stegeman CA, et al. Trends in the incidence of treated end-stage renal failure in The Netherlands: hope for the future? Kidney Int 2004; Suppl 92: 7-10
11. Witte EC, Lambers Heerspink HJ, de Zeeuw D, et al. First morning voids are more reliable than spot urine samples to assess microalbu-minuria? J Am Soc Nephrol 2009; 20: 436-443
12. Halbesma A, Kuiken DS, Brantsma AH, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol 2006; 17: 2582-2590
13. Van der Velde M, Halbesma N, de Charro FT, et al. Screening for albuminuria identifies individuals at increased renal risk. J Am Soc Nephrol 2009; 20: 852-862
14. Brantsma AH, Bakker SJL, Hillege HL, et al. Cardiovascular and renal outcome in subjects with K/DOQ1 stage 1-3 chronic kidney disease: the importance of urinary albumin excretion. Nephrol Dial Transplant 2008; 23: 3851-3858